nature portfolio

Corresponding author(s):	Michael Garton
Last updated by author(s):	Nov 27, 2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

~		4.0			
< ⋅	トつ	1	ıct	11.	CS
٠,			151	- 11	, n

n/a	Confirmed
	$oxed{\boxtimes}$ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	🔀 A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	A description of all covariates tested
	🔀 A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
	$oxed{\boxtimes}$ Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

No software was used

Data analysis

pingouin 0.5.2, alphafold 2.0.0, Clustal Omega 1.2.4, MMSeqs2 (release Feb 24, 2021), SPOT-1D (original release), FreeSASA 2.1.0, PhyML 3.0, torchmetrics 0.8.1, pytorch-lightning 1.6.5, pytorch 1.12.1, scikit-learn 1.2.21, wandb 0.15.01, CHARMM-GUI server v3.8, GROMACS/2021.3, Protein Imager 0.5.60, https://doi.org/10.24433/CO.2530457.v2

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Sequences of all 711 natural hexon can be found at /data/hexon_711.fasta in the CodeOcean capsule (https://doi.org/10.24433/CO.2530457.v2). All natural hexon sequences were downloaded from the UniprotKB26,37 database. Source data are provided with this paper.

Human rese	arch parti	cipants			
Policy information	about <u>studies ir</u>	nvolving human research participants and Sex and Gender in Research.			
Reporting on sex	and gender	N/A			
Population characteristics N/A		N/A			
Recruitment N/A		N/A			
Ethics oversight N/A		N/A			
Note that full informa	ation on the appr	oval of the study protocol must also be provided in the manuscript.			
Field-specific reporting					
		s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.			
Life sciences	В	ehavioural & social sciences			
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf					
Life scier	nces stu	udy design			
All studies must dis	sclose on these	points even when the disclosure is negative.			
Sample size	Sample size was	s chosen based on total publicly available data (711 adenovirus hexon sequences).			
Data exclusions	Adenovirus hex	on sequence below a certain length threshold were excluded on the basis that they were incomplete			
Replication	Study reports a	new machine learning model and therefore does not report experimental findings			
Randomization	Sequences were	e randomly split into the training/validation/test set at a ratio of 7/2/1 to avoid bias in training and evaluation			
Blinding	Blinding was not relevant as the study is computational and the outcomes are algorithm dependent, therefore not subject to human biases that would warrant blinding.				
Reportin	g for sp	pecific materials, systems and methods			
We require informati	on from authors	about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.			
Materials & ex	perimental s	ystems Methods			
n/a Involved in th					
	Antibodies ChIP-seq				
Palaeontol	Palaeontology and archaeology MRI-based neuroimaging				

Animals and other organisms

Dual use research of concern

Clinical data